Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 51: 1165-1176, 2005. First published May 12, 2005; 10.1373/clinchem.2005.049429
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2005.049429v1
51/7/1165    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (38)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FitzGerald, S. P.
Right arrow Articles by Benchikh, E. O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FitzGerald, S. P.
Right arrow Articles by Benchikh, E. O.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2005;51:1165-1176.)
© 2005 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Development of a High-Throughput Automated Analyzer Using Biochip Array Technology

Stephen P. FitzGerald, John V. Lamonta, Robert I. McConnell and El O. Benchikh

1 Randox Laboratories, Crumlin, United Kingdom.

aAddress correspondence to this author at: Randox Laboratories, 55 Diamond Rd., Crumlin, County Antrim, BT29 4QY United Kingdom. Fax 44-2894-452912; e-mail john.lamont{at}randox.com.

Background: Use of protein array technology over conventional assay methods has advantages that include simultaneous detection of multiple analytes, reduction in sample and reagent volumes, and high output of test results. The susceptibility of ligands to denaturation, however, has impeded production of a stable, reproducible biochip platform, limiting most array assays to manual or, at most, semiautomated processing techniques. Such limitations may be overcome by novel biochip fabrication procedures.

Methods: After selection of a suitable biochip substrate, biochip surfaces were chemically modified and assessed to enable optimization of biochip fabrication procedures for different test panels. The assay procedure was then automated on a dedicated instrument, and assay performance was determined for a panel of cytokine markers. Assay results were then compared with a commercial method for measurement of cytokine markers.

Results: Secondary ion mass spectrometry and x-ray photoelectron spectroscopy demonstrated appropriate and reproducible modification of the biochip surface. Contact-angle studies also confirmed generation of hydrophobic surfaces that enabled containment of droplets for fabrication of discrete test regions. Automation of the biochip assays on a dedicated instrument produced excellent cytokine marker performance with intra- and interassay imprecision <10% for most analytes. Comparison studies showed good agreement with other methods (r = 0.95–0.99) for cytokines.

Conclusion: Performance data from this automated biochip array analyzer provide evidence that it is now possible to produce stable and reproducible biochips for output of more than 2000 test results per hour.




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. Wu, F. Yan, X. Zhang, Y. Yan, J. Tang, and H. Ju
Disposable Reagentless Electrochemical Immunosensor Array Based on a Biopolymer/Sol-Gel Membrane for Simultaneous Measurement of Several Tumor Markers
Clin. Chem., September 1, 2008; 54(9): 1481 - 1488.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
M. Settergren, F. Bohm, L. Ryden, and J. Pernow
Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease
Eur. Heart J., July 2, 2008; 29(14): 1753 - 1760.
[Abstract] [Full Text] [PDF]

Home page
 CJASNHome page
S. Badiou, J.-P. Cristol, I. Jaussent, N. Terrier, M. Morena, F. Maurice, H. Leray-Moragues, J.-P. Rivory, L. Chalabi, C. Delcourt, et al.
Fine-Tuning of the Prediction of Mortality in Hemodialysis Patients by Use of Cytokine Proteomic Determination
Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 423 - 430.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. A. Kavsak, D. T. Ko, A. M. Newman, G. E. Palomaki, V. Lustig, A. R. MacRae, and A. S. Jaffe
Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide
Clin. Chem., December 1, 2007; 53(12): 2112 - 2118.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
H. Berrahmoune, J. V. Lamont, B. Herbeth, P. S. FitzGerald, and S. Visvikis-Siest
Biological Determinants of and Reference Values for Plasma Interleukin-8, Monocyte Chemoattractant Protein-1, Epidermal Growth Factor, and Vascular Endothelial Growth Factor: Results from the STANISLAS Cohort
Clin. Chem., March 1, 2006; 52(3): 504 - 510.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.